N4-acylcytosine nucleosides for treatment of viral infections
US7105527B2 · kind B2 · utility
1Cited by
6References
36Claims
0Family size
Inventors
Key dates
| Filing date | Dec 13, 2002 |
| Grant date | Sep 12, 2006 |
| Priority date | — |
| Expiry date | Dec 13, 2022 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07H19/16
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to a method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N4-acyl-2′,3′-dideoxy-5-fluorocytidine or N4-acyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine, and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.